Antiviral Activity of Influenza A Virus Defective Interfering Particles against SARS-CoV-2 Replication In Vitro through Stimulation of Innate Immunity

Article activity feed

1. Version published to 10.3390/cells10071756

   Jul 11, 2021
2. 

   Version published to 10.1101/2021.02.19.431972v2 on bioRxiv

   Jun 25, 2021
3. 

   ScreenIT

   Mar 1, 2021

   SciScore for 10.1101/2021.02.19.431972: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Antibody labelling was performed with mouse anti-SARS-CoV-2 S protein (Abcalis, clone AB68-A09, #ABK68-A09-M) and secondary antibody anti-mouse Alexa488 (Cell Signaling Technology, #4408), each step followed by three washing steps with PBS containing 0.05% Tween-20.	anti-SARS-CoV-2 S protein (Abcalis, suggested: None #ABK68-A09-M suggested: None anti-mouse suggested: (Cell Signaling Technology Cat# 4408, RRID:AB_10694704)
   Experimental Models: Cell Lines
   Sentences	R…

   SciScore for 10.1101/2021.02.19.431972: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Antibody labelling was performed with mouse anti-SARS-CoV-2 S protein (Abcalis, clone AB68-A09, #ABK68-A09-M) and secondary antibody anti-mouse Alexa488 (Cell Signaling Technology, #4408), each step followed by three washing steps with PBS containing 0.05% Tween-20.	anti-SARS-CoV-2 S protein (Abcalis, suggested: None #ABK68-A09-M suggested: None anti-mouse suggested: (Cell Signaling Technology Cat# 4408, RRID:AB_10694704)
   Experimental Models: Cell Lines
   Sentences	Resources
   The SARS-CoV-2 seed virus was produced in Caco-2 cells, and virus particles were enriched in Vivaspin 20 columns (Sartorius Stedim, Biotech) via centrifugation.	Caco-2 suggested: None
   Samples were serially diluted in 10-fold steps, and used to infect a confluent monolayer of Vero-6 cells (on 96-well plates) for 1 h.	Vero-6 suggested: None
   SARS-CoV-2 infection and antiviral treatment: Confluent Calu-3 cells in 96-well plates (~6 × 104 cells/well) were infected with SARS-CoV-2 (2000 PFU per well).	Calu-3 suggested: None

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

   This has a caveat, though, as a decrease in mortality was observed for patients requiring oxygen (including mechanical ventilation), but an increase in mortality was reported for patients not requiring oxygen (Horby et al., 2020). Treatment of COVID-19 patients with IFNs has not been approved yet. In general, SARS-CoV-2 infection modulates and inhibits the IFN response (Chen et al., 2020a, Konno et al., 2020, Lei et al., 2020). Moreover, it was recently shown that the host cell entry receptor ACE2 is indeed an ISG, and it was speculated that SARS-CoV-2 may exploit the IFN-driven upregulation of ACE2 to enhance infection (Ziegler et al., 2020). However, SARS-CoV-2 replication was also shown to be susceptible to inhibition by exogenously added IFN. For instance, all IFNs (type I, II and III) exhibited potent antiviral activity with SARS-CoV-2 replication in vitro (Busnadiego et al., 2020, Felgenhauer et al., 2020), suggesting that the antiviral activities of IFNs may counterbalance any proviral effects derived from ACE2 induction. In agreement with this, intranasal IFN-I administration (in hamsters) pre- or post-virus challenge was shown to reduce SARS-CoV-2 disease burden (Hoagland et al., 2021). Moreover, in a placebo-controlled phase 2 clinical trial, administration of inhaled, nebulized IFN beta-1a resulted in a higher chance of disease improvement and a more rapid recovery from COVID-19 (Monk et al., 2020). In our cell culture experiments, IAV DIPs completely abrogated SAR...

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Read the original source
4. 

   Version published to 10.1101/2021.02.19.431972v1 on bioRxiv

   Feb 19, 2021